Back

The impact of vaccination strategies for COVID-19 in the context of emerging variants and increasing social mixing in Bogota, Colombia: a mathematical modelling study

Espana, G.; Cucunuba, Z. M.; Cuervo-Rojas, J.; Diaz, H.; Gonzalez-Mayorga, M.; Ramirez, J. D.

2021-09-07 epidemiology
10.1101/2021.08.06.21261734 medRxiv
Show abstract

BackgroundIn Bogota by August 1st, more than 27,000 COVID-19 deaths have been reported, while complete and partial vaccination coverage reached 30% and 37%, respectively. Although reported cases are decreasing, the potential impact of new variants is uncertain. MethodsWe used an agent-based model of COVID-19 calibrated to local data. Variants and vaccination strategies were included. We estimated the impact of vaccination and modelled scenarios of early and delayed introduction of the delta variant, along with changes in mobility, social contact, and vaccine uptake over the next months. FindingsBy mid-July, vaccination may have prevented 17,800 (95% CrI: 16,000 - 19,000) deaths in Bogota. We found that delta could lead to a fourth wave of magnitude and timing dependent on social mixing, vaccination strategy, and delta dominance. In scenarios of early dominance of delta by mid-July, age prioritization and maintaining the interval between doses were important factors to avert deaths. However, if delta dominance occurred after mid-September, age prioritization would be less relevant, and the magnitude of a four wave would be smaller. In all scenarios, higher social mixing increased the magnitude of the fourth wave. Increasing vaccination rates from 50,000/day to 100,000/day reduced the impact of a fourth wave due to delta. InterpretationThe magnitude and timing of a potential fourth wave in Bogota caused by delta would depend on social mixing and the timing of dominance. Rapidly increasing vaccination coverage with non-delayed second doses could reduce the burden of a new wave. FundingNSF RAPID DEB 2027718. HERMES 50419. Medical Research Council. MR/R024855/1 Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSThe impact of vaccination strategies in the context of emerging SARS-CoV-2 variants and increasing social mixing in Colombia had not been previously evaluated through mathematical modelling. We searched PubMed for modelling studies using the terms "COVID-19 vaccine AND model AND variant AND Colombia" or "SARS-CoV-2 AND vaccine AND model AND variant AND Colombia" (From 2021/1/1 to 2021/07/31). We did not find studies addressing this question. However, we found a model describing the evolution of the epidemic in the country during the first year, and research on the emergence of alpha, gamma, and B.1.621 variants in Colombia. We extended a previous version of our SARS-CoV-2 agent-based model for Bogota to include the potential effect of vaccination and variants. This model simulates transmission of SARS-CoV-2 based on daily activity patterns of a synthetic population, representing demographic and geographic characteristics of the total population of the city. Added value of this studyFirst, our study provides a preliminary estimate of the impact of the vaccination program in Bogota in terms of the number of deaths prevented. The second major finding is the indication that due to the introduction of the delta variant in the city, and based on the current knowledge of its biology, there is a risk of a fourth epidemic wave, whose time of occurrence and magnitude would depend mainly on three factors: when delta becomes dominant, the intensity of social contact, and vaccination roll-out strategy and coverage. Implications of all the available evidenceWe estimate that by mid-July, vaccination may have already prevented 17,800 (95% CrI: 16,000 - 19,000) deaths in Bogota. The delta variant could become dominant and lead to a fourth wave later in the year, but its timing will depend on the date of introduction, social mixing patterns, and vaccination strategy. In all scenarios, higher social mixing is associated with a fourth wave of considerable magnitude. If an early delta introduction occurred (dominance by mid-July), a new wave may occur in August/September and in such case, age prioritization of vaccination and maintaining the 21-day interval between doses of the Pfizer-BioNTech BNT162b2 are more important. However, if introduction occurred one or two months later (with dominance by mid-August/September) a fourth wave would be of smaller magnitude, the age-prioritization is less relevant, but maintaining the dose scheme without postponement is more important. In all scenarios we found that increasing the vaccination rate from the current average of 50,000/day to 100,000/day reduces the impact of a potential fourth wave due to the delta variant. Our study indicates that given the possibility of a fourth wave in the city, it is necessary to continue maintaining adherence to non-pharmacological interventions, such as the use of face masks and physical distancing, to be cautious with the intensification of social activities, and that it is essential to increase the current pace of vaccinations to rapidly reach high vaccination coverage in the population of the city.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
BMC Public Health
147 papers in training set
Top 0.1%
22.7%
2
PLOS ONE
4510 papers in training set
Top 22%
8.5%
3
Frontiers in Public Health
140 papers in training set
Top 0.5%
7.2%
4
BMC Medicine
163 papers in training set
Top 0.7%
4.9%
5
BMC Infectious Diseases
118 papers in training set
Top 0.7%
4.3%
6
Vaccines
196 papers in training set
Top 0.8%
2.7%
50% of probability mass above
7
PeerJ
261 papers in training set
Top 5%
2.1%
8
The Lancet Regional Health - Americas
22 papers in training set
Top 0.1%
1.9%
9
The Lancet Public Health
20 papers in training set
Top 0.2%
1.9%
10
Scientific Reports
3102 papers in training set
Top 55%
1.8%
11
BMJ Open
554 papers in training set
Top 9%
1.8%
12
Epidemics
104 papers in training set
Top 0.9%
1.7%
13
Infectious Disease Modelling
50 papers in training set
Top 0.8%
1.7%
14
JMIR Public Health and Surveillance
45 papers in training set
Top 2%
1.7%
15
American Journal of Epidemiology
57 papers in training set
Top 0.8%
1.5%
16
PLOS Medicine
98 papers in training set
Top 3%
1.5%
17
Viruses
318 papers in training set
Top 3%
1.5%
18
Epidemiology and Infection
84 papers in training set
Top 2%
1.5%
19
Eurosurveillance
80 papers in training set
Top 0.9%
1.3%
20
The Lancet Regional Health - Europe
32 papers in training set
Top 0.2%
1.2%
21
International Journal of Infectious Diseases
126 papers in training set
Top 2%
1.2%
22
The Lancet Infectious Diseases
71 papers in training set
Top 2%
1.1%
23
PLOS Neglected Tropical Diseases
378 papers in training set
Top 4%
1.1%
24
JAMA Network Open
127 papers in training set
Top 3%
1.1%
25
Journal of Medical Virology
137 papers in training set
Top 4%
0.8%
26
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 4%
0.8%
27
American Journal of Preventive Medicine
11 papers in training set
Top 0.5%
0.8%
28
Emerging Infectious Diseases
103 papers in training set
Top 3%
0.7%
29
Travel Medicine and Infectious Disease
15 papers in training set
Top 0.7%
0.7%
30
Royal Society Open Science
193 papers in training set
Top 5%
0.7%